Review: A selection of Lancet research highlights for July 11, 2020

!----Rusolitini cream is used in the treatment of vitiligo: https://doi.org/10.1016/S0140-6736 (20) 30609-7 vitiligo is a chronic autoimmune disease that causes skin pigmentation loss and a decline in quality of lifecurrently effective glyceme therapy, researchers recently examined the therapeutic potential of Rusolitini cream for patients with vitiligo0.5% or more of the facial surface area (BSA) and 3% or more of non-facial BSA decolorization patients received Russoline cream or placebo, the main endpoint was the proportion of patients with a 50% or higher percentage of patients with a 50% or higher scoring index of facial vitiligo area in the 24th week than the baseline (F-VASI50)157 patients (average age, 48.3 years, 73 men and 84 women) participated in the study, of which 32 (20%) were in the control group and 31 (20%) were 0.1 5% of the daily group, 31 cases (20%) for 0.5% daily group, 30 cases (19%) for 1.5% of the daily group, 33 cases (21%) for 1.5% of the daily grouppatients who used 1.5% of Russolitini cream twice daily (15/33) and 1.5% daily (15/30), and significantly higher than those who reached F-VASI50 at week 24 (1/32)4 patients with severe adverse events, none of which were related to the study treatmentthe most common adverse event in the Rusolitini group is itching13 (10%) of 125 patients receiving Rusolitenini cream and 1 (3%) of 32 patients receiving the control group cream developed acne, which was considered to be a treatment-related adverse eventall adverse events associated with treatment are mild or moderate2Gender differences in cardiovascular disease risk, treatment, morbidity and mortality doI: https://doi.org/10.1016/S0140-6736 (20) 30543-2 from high-income countries (HICS) studies show that women receive less cardiovascular disease care (surveys and treatment) than men, leading to a higher risk of deathHowever, few studies systematically report data on risk factors, primary or secondary preventive drug use, the incidence of cardiovascular disease or community deathsGiven that most cardiovascular diseases occur in low- and middle-income countries (LMICs), it is necessary to compare the treatment and outcomes of both male and female patients with HICS and LMIC2005-2019, a total of 20,2072 participants were surveyed, with an average age of 50.8 years for female participants and 51.7 years for men, with an average follow-up of 9.5 yearswomen have a lower risk of cardiovascular disease than men, according to the INTERHEART and Framingham assessment systemsthe proportion of women taking primary preventive measures (taking healthy lifestyle behaviours and using proven drugs) is higher than that of men per 1,000 follow-up years, there were 4.1 cardiovascular events in women, 6.4 in men (HR-0.75), 4.5 deaths in women and 7.4 cases for men (0.62) , in contrast, women received lower rates of secondary preventive measures, heart tests and coronary artery reconstruction than men overall, women had a lower risk of recurrent cardiovascular disease than men (20.0 vs 27.7 per 1000 follow-up years, HR-0.73) 30 days of mortality among women (22 percent vs 28 percent) in patients with new cardiovascular events the differences in treatment and outcomes between men and women in low-income countries are more pronounced than in high-income countries 3 New Target Drug Joint Application Promises To Significantly Reduce Risk of Death in Patients with Heart Failure DOI: https://doi.org/10.1016/S0140-6736 (20) 30748-0 Study Finds Salt Corticosteroid Receptor Antagonaine (Mras), Agiotensin receptor-neprisin inhibitor (ARNIS) and Sodium/Glucose Conjugon 2 (SGLT2), which reduce the mortality of patients with poor blood scores (ARBS) and beta blockers in conventional treatments (angiotensin-converting enzymes (ACE), angiotensin receptor blockers (ARBS) and beta blockers, and HFrEF patients, and researchers recently examined the therapeutic effects of these three combination of therapies this study compared the efficacy of disease remission therapy (ARNI, MRA, SGLT2, and beta blockers) with traditional therapies (ACE, ARB, and beta blockers) in the treatment of HFrEF the main endpoint is the combined endpoint of cardiovascular death and heart failure hospitalization Compared with traditional treatment options, the risk of cardiovascular death and hospitalization of patients with comprehensive disease improvement treatment was 0.38, 0.50 was only at the end of cardiovascular death, the risk of hospitalization for heart failure was 0.32 and the risk of death was 0.53 patients treated with comprehensive disease improvement treatment, the duration of hospital admission without blood vessels or heart failure can increase by 2.7 years (patients aged 80 years) to 8.3 years (55 years of age), and after onset survival can increase by 1.4 years (80 years of age) to 6.3 years (80 years of age) Source: MedSci Original !-- Content Presentation Ends -- !-- Determine Signed-off Ends